M

Mineralys Therapeutics Inc
NASDAQ:MLYS

Watchlist Manager
Mineralys Therapeutics Inc
NASDAQ:MLYS
Watchlist
Price: 35.66 USD -0.14% Market Closed
Market Cap: 2.8B USD

Mineralys Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mineralys Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
M
Mineralys Therapeutics Inc
NASDAQ:MLYS
EPS (Diluted)
-$3
CAGR 3-Years
-92%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

Mineralys Therapeutics Inc
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

MLYS Intrinsic Value
Not Available
M

See Also

What is Mineralys Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-3.7 USD

Based on the financial report for Dec 31, 2024, Mineralys Therapeutics Inc's EPS (Diluted) amounts to -3.7 USD.

What is Mineralys Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-92%

Over the last year, the EPS (Diluted) growth was -84%. The average annual EPS (Diluted) growth rates for Mineralys Therapeutics Inc have been -92% over the past three years .

Back to Top